A comparative study of visual function, QOL, and satisfaction in patients with BRVO or CRVO macular edema being treated with existing anti-VEGF agents, before and after switching to ranibizumab BS

A comparative study of visual function, QOL, and satisfaction in patients with BRVO or CRVO macular edema being treated with existing anti-VEGF agents, before and after switching to ranibizumab BS - A comparative study of visual function, QOL, and satisfaction in patients with RVO, before and after switching to ranibizumab BS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055074

Enrollment

Registered

2024-07-25

Start date

2024-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein Occlusion Central Retinal Vein Occlusion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients attend to the ophthalmology department of Nippon Medical School Hospital who diagnosed with BRVO or CRVO, had been treated with existing anti-VEGF agents for the past 6 months, and request to switch to ranibizumab BS.

Exclusion criteria

Exclusion criteria: Moderate or higher myopia/cataract Patients with eye diseases that impair visual function other than vitreoretinal diseases Patients who have undergone other intraocular surgery Patients for whom no CME reduction effect is observed with existing anti-VEGF agents Patients judged to be inappropriate by the research director

Design outcomes

Primary

Measure	Time frame
Visual function (visual acuity)	—

Secondary

Measure	Time frame
Visual function (metamorphopsia, anisotropia, contrast sensitivity, stereopsis) Number of ranibizumab BS injections, injection interval (number of recurrences, duration) Vision-related QOL Patient satisfaction	—

Countries

Japan

Contacts

Public ContactFumiki Okamoto

Nippon Medical School Hospital Ophthalmology

f-okamoto@nms.ac.jp03-3822-2131

Outcome results